The stomach is the most common site of @entity674 ( @entity674 ), but the surgical outcomes of @entity1820 in the era of targeted drug therapy are unclear. This study aimed to assess factors associated with adverse outcomes and to analyze the effects of targeted drug therapy on @entity1820 . The surgical outcomes and follow-up records of consecutive @entity1 with @entity1820 treated at Tianjin Medical University Cancer Institute _ Hospital between June 2002 and December 2008 were reviewed. Eighty-five @entity1 were included. Surgery was undertaken in all @entity1 with curative intent. @entity2213 was administered preoperatively to 6 (7%) @entity1 (neoadjuvant therapy), and the median durations of therapy were 6 months (range 3-17 months). @entity2213 was administered postoperatively to 18 (21%) @entity1 with high-risk lesions (adjuvant therapy) and 19 (22%) @entity1 with recurrent disease, and the median durations of therapy were 22 months (range 6-24 months) and 25 months (range 1-64 months), respectively. @entity5 size greater than 10 cm (P = 0.015), high mitotic index (P = 0.021), and no adjuvant @entity2213 therapy (P = 0.046) were the only significant factors associated with higher recurrence-free survival in multivariate analysis. Large @entity5 , high mitotic index, and the absence of @entity2213 treatment are associated with high recurrence-free survival. Adjuvant @entity2213 therapy of 2 years appears to decrease the recurrence of @entity1820 .

Surgical outcomes of XXXX of the stomach: a single unit experience in the era of targeted drug therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumor', 'tumors'] @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastric GISTs'] @entity674 :: ('MESH:D046152', 'Disease') :: ['GISTs', 'gastrointestinal stromal tumors'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib mesylate']
@entity674 :: (MESH:D046152,Disease) :: ['gastrointestinal stromal tumors']
